Vitamin C attenuates primate bone marrow aging at the molecular and progenitor level.
Key claim: Long-term oral vitamin C supplementation attenuates selected molecular and progenitor-level features of bone marrow aging in primates, expanding common lymphoid progenitors, rebalancing HSPC lineage output, and reducing transcriptomic age by about four years.
Abstract
Bone marrow aging compromises hematopoiesis and immunity, yet whether these processes are modifiable in primates remains unexplored. Here, we map the single-cell transcriptomic landscape of primate bone marrow aging and demonstrate that long-term oral vitamin C (VC) supplementation attenuates selected molecular and progenitor-level decline. Aging drives severe common lymphoid progenitor (CLP) depletion, myeloid-biased hematopoietic stem and progenitor cell (HSPC) output, and anatomical site-specific molecular adaptations. VC administration partially offsets these phenotypes, expanding the CLP pool and rebalancing lineage commitment trajectories. This aligns with a ∼4-year reduction in transcriptomic age estimates, cross-validated by an epigenetic clock. Cell-cell communication analyses revealed that VC remodels intercellular signaling, nominating a VC-responsive, progranulin (GRN)-linked candidate pathway. In parallel, human in vitro assays demonstrate that recombinant progranulin mirrors selected VC-associated molecular actions. Collectively, these findings delineate the molecular architecture of primate bone marrow aging and nominate modifiable pathways for further investigation.
Why this matters
This is the first primate-level interventional readout showing that a cheap, oral, well-tolerated nutrient can move both progenitor composition (CLP expansion, reduced myeloid bias) and multiple molecular age clocks in bone marrow — a compartment central to immunosenescence and clonal hematopoiesis. It narrows the model-to-human translation gap that plagues most bone-marrow rejuvenation candidates, while leaving open whether the ~4-year transcriptomic-age delta corresponds to any functional immune benefit in humans.